TY  - CONF
AU  - Bangay, Gabrielle
AU  - Isca, Vera
AU  - Domínguez-Martín, Eva María
AU  - Santos, Daniel J.V.A.
AU  - Díaz-Lanza, Ana María
AU  - Saraiva, Lucília
AU  - Afonso, Carlos A.M.
AU  - Jovanović, Mirna
AU  - Pešić, Milica
AU  - Rijo, Patricia
PY  - 2023
UR  - https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0043-1774270
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6435
AB  - Multidrug resistant (MDR) cancer cases continue to increase, such that the search for novel and more effective anti-cancer therapeutics is of high priority. In some MDR cancers, the overexpression of membrane transport proteins, like P-glycoprotein (P-gp), continues to be a major impediment to successful therapy. Plectranthus genus (Lamiaceae), known for their medicinal and therapeutic properties, is a well-known source of bioactive diterpenoids, such as 7α-acetoxy-6β-hydroxyroyleanone (Roy) and 6,7- dehydroroyleanone (DeRoy). Based on in silico molecular docking studies, a small library of semi-synthetic derivates was prepared. The antitumoural activity of the compounds was assessed in resistant human cancer cell lines NCI-H460/R and DLD1-TxR. Cell viability was assessed using MTT assay and cell death induction by Annexin V/PI. Overall, it was demonstrated that three of the abietane diterpenoid analogues induced P-gp inhibition in MDR cancer cell lines, presenting novel selective compounds for the possible treatment of lung and colon cancer. Moreover, Roy and DeRoy nano-formulations were successfully prepared. DeRoy hybrid nanoparticles significantly increased the efficacy of DeRoy in NCI-H460 and NCI- H460/R. Roy, conjugated with oleic acid afforded self-assembly nanoparticles, to improve aqueous solubility and bioavailability of Roy. This new nano formulation did not decrease cell viability of Vero-E6 cells when compared to Roy with potential as a pro-drug delivery system. Currently, top hit derivatives are being prepared into nano-formulations for prospective pharmaceutical use as P-gp modulators.
PB  - Georg Thieme Verlag KG
C3  - 71st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA); 2023 Jul 2-5; Dublin, Ireland
T1  - New formulations with royleanone derivatives from Plectranthus spp. to inhibit P-glycoprotein activity
DO  - 10.1055/s-0043-1774270
SP  - 1424
ER  - 

@conference{
author = "Bangay, Gabrielle and Isca, Vera and Domínguez-Martín, Eva María and Santos, Daniel J.V.A. and Díaz-Lanza, Ana María and Saraiva, Lucília and Afonso, Carlos A.M. and Jovanović, Mirna and Pešić, Milica and Rijo, Patricia",
year = "2023",
abstract = "Multidrug resistant (MDR) cancer cases continue to increase, such that the search for novel and more effective anti-cancer therapeutics is of high priority. In some MDR cancers, the overexpression of membrane transport proteins, like P-glycoprotein (P-gp), continues to be a major impediment to successful therapy. Plectranthus genus (Lamiaceae), known for their medicinal and therapeutic properties, is a well-known source of bioactive diterpenoids, such as 7α-acetoxy-6β-hydroxyroyleanone (Roy) and 6,7- dehydroroyleanone (DeRoy). Based on in silico molecular docking studies, a small library of semi-synthetic derivates was prepared. The antitumoural activity of the compounds was assessed in resistant human cancer cell lines NCI-H460/R and DLD1-TxR. Cell viability was assessed using MTT assay and cell death induction by Annexin V/PI. Overall, it was demonstrated that three of the abietane diterpenoid analogues induced P-gp inhibition in MDR cancer cell lines, presenting novel selective compounds for the possible treatment of lung and colon cancer. Moreover, Roy and DeRoy nano-formulations were successfully prepared. DeRoy hybrid nanoparticles significantly increased the efficacy of DeRoy in NCI-H460 and NCI- H460/R. Roy, conjugated with oleic acid afforded self-assembly nanoparticles, to improve aqueous solubility and bioavailability of Roy. This new nano formulation did not decrease cell viability of Vero-E6 cells when compared to Roy with potential as a pro-drug delivery system. Currently, top hit derivatives are being prepared into nano-formulations for prospective pharmaceutical use as P-gp modulators.",
publisher = "Georg Thieme Verlag KG",
journal = "71st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA); 2023 Jul 2-5; Dublin, Ireland",
title = "New formulations with royleanone derivatives from Plectranthus spp. to inhibit P-glycoprotein activity",
doi = "10.1055/s-0043-1774270",
pages = "1424"
}

Bangay, G., Isca, V., Domínguez-Martín, E. M., Santos, D. J.V.A., Díaz-Lanza, A. M., Saraiva, L., Afonso, C. A.M., Jovanović, M., Pešić, M.,& Rijo, P.. (2023). New formulations with royleanone derivatives from Plectranthus spp. to inhibit P-glycoprotein activity. in 71st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA); 2023 Jul 2-5; Dublin, Ireland
Georg Thieme Verlag KG., 1424.
https://doi.org/10.1055/s-0043-1774270

Bangay G, Isca V, Domínguez-Martín EM, Santos DJ, Díaz-Lanza AM, Saraiva L, Afonso CA, Jovanović M, Pešić M, Rijo P. New formulations with royleanone derivatives from Plectranthus spp. to inhibit P-glycoprotein activity. in 71st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA); 2023 Jul 2-5; Dublin, Ireland. 2023;:1424.
doi:10.1055/s-0043-1774270 .

Bangay, Gabrielle, Isca, Vera, Domínguez-Martín, Eva María, Santos, Daniel J.V.A., Díaz-Lanza, Ana María, Saraiva, Lucília, Afonso, Carlos A.M., Jovanović, Mirna, Pešić, Milica, Rijo, Patricia, "New formulations with royleanone derivatives from Plectranthus spp. to inhibit P-glycoprotein activity" in 71st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA); 2023 Jul 2-5; Dublin, Ireland (2023):1424,
https://doi.org/10.1055/s-0043-1774270 . .

TY  - JOUR
AU  - Neto, Iris
AU  - Domínguez-Martín, Eva María
AU  - Ntungwe, Epole
AU  - Reis, Catarina
AU  - Pešić, Milica
AU  - Faustino, Célia
AU  - Rijo, Patrícia
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4262
AB  - The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden challenge, minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), MBIC with Bioburden challenge and growth curve studies. Toxicological studies (Artemia salina, sulforhodamine B (SRB) assay) were done to assess if the compound had antimicrobial and not cytotoxic properties. Furthermore, microencapsulation and stability studies were carried out to evaluate the chemical behavior and stability of DHA. On MIC results, Gram-positive bacteria Staphylococcus aureus ATCC 1228 and Mycobacterium smegmatis ATCC 607 presented a high efficiency (7.81 µg/mL), while on Gram-negative bacteria the highest MIC value of 125 µg/mL was obtained by all Klebsiella pneumoniae strains and Escherichia coli isolate strain HSM 303. Bioburden challenge showed that MIC, MBIC and percentage biofilm inhibition (BI) values suffered alterations, therefore, having higher concentrations. MBIC values demonstrated that DHA has a higher efficiency against S. aureus ATCC 43866 with a percentage of BI of 75.13 ± 0.82% at 0.49 µg/mL. Growth curve kinetic profiles of DHA against S. aureus ATCC 25923 were observed to be bacteriostatic. DHA-alginate beads had a average size of 2.37 ± 0.20 and 2.31 ± 0.17 × 103 µm2 with an encapsulation efficiency (EE%) around 99.49 ± 0.05%, a protection percentage (PP%) of 60.00 ± 0.05% in the gastric environment and a protection efficiency (PE%) around 88.12 ± 0.05% against UV light. In toxicological studies DHA has shown IC50 of 19.59 ± 7.40 µg/mL and a LC50 of 21.71 ± 2.18%. The obtained results indicate that DHA is a promising antimicrobial candidate against a wide range of bacteria and biofilm formation that must be further explored.
PB  - Basel : MDPI
T2  - Pharmaceutics
T1  - Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
IS  - 6
VL  - 13
DO  - 10.3390/pharmaceutics13060825
SP  - 825
ER  - 

@article{
author = "Neto, Iris and Domínguez-Martín, Eva María and Ntungwe, Epole and Reis, Catarina and Pešić, Milica and Faustino, Célia and Rijo, Patrícia",
year = "2021",
abstract = "The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden challenge, minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), MBIC with Bioburden challenge and growth curve studies. Toxicological studies (Artemia salina, sulforhodamine B (SRB) assay) were done to assess if the compound had antimicrobial and not cytotoxic properties. Furthermore, microencapsulation and stability studies were carried out to evaluate the chemical behavior and stability of DHA. On MIC results, Gram-positive bacteria Staphylococcus aureus ATCC 1228 and Mycobacterium smegmatis ATCC 607 presented a high efficiency (7.81 µg/mL), while on Gram-negative bacteria the highest MIC value of 125 µg/mL was obtained by all Klebsiella pneumoniae strains and Escherichia coli isolate strain HSM 303. Bioburden challenge showed that MIC, MBIC and percentage biofilm inhibition (BI) values suffered alterations, therefore, having higher concentrations. MBIC values demonstrated that DHA has a higher efficiency against S. aureus ATCC 43866 with a percentage of BI of 75.13 ± 0.82% at 0.49 µg/mL. Growth curve kinetic profiles of DHA against S. aureus ATCC 25923 were observed to be bacteriostatic. DHA-alginate beads had a average size of 2.37 ± 0.20 and 2.31 ± 0.17 × 103 µm2 with an encapsulation efficiency (EE%) around 99.49 ± 0.05%, a protection percentage (PP%) of 60.00 ± 0.05% in the gastric environment and a protection efficiency (PE%) around 88.12 ± 0.05% against UV light. In toxicological studies DHA has shown IC50 of 19.59 ± 7.40 µg/mL and a LC50 of 21.71 ± 2.18%. The obtained results indicate that DHA is a promising antimicrobial candidate against a wide range of bacteria and biofilm formation that must be further explored.",
publisher = "Basel : MDPI",
journal = "Pharmaceutics",
title = "Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment",
number = "6",
volume = "13",
doi = "10.3390/pharmaceutics13060825",
pages = "825"
}

Neto, I., Domínguez-Martín, E. M., Ntungwe, E., Reis, C., Pešić, M., Faustino, C.,& Rijo, P.. (2021). Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment. in Pharmaceutics
Basel : MDPI., 13(6), 825.
https://doi.org/10.3390/pharmaceutics13060825

Neto I, Domínguez-Martín EM, Ntungwe E, Reis C, Pešić M, Faustino C, Rijo P. Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment. in Pharmaceutics. 2021;13(6):825.
doi:10.3390/pharmaceutics13060825 .

Neto, Iris, Domínguez-Martín, Eva María, Ntungwe, Epole, Reis, Catarina, Pešić, Milica, Faustino, Célia, Rijo, Patrícia, "Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment" in Pharmaceutics, 13, no. 6 (2021):825,
https://doi.org/10.3390/pharmaceutics13060825 . .